Neoadjuvant Cisplatin, Methotrexate and Vinblastine for Muscle-Invasive Bladder Cancer: Long-Term Followup
- 1 September 1993
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 150 (3) , 849-852
- https://doi.org/10.1016/s0022-5347(17)35630-6
Abstract
A total of 26 patients with locally advanced bladder cancer received chemotherapy consisting of cisplatin, methotrexate and vinblastine. Radical cystectomy was performed in 24 of 26 patients (92%) receiving neoadjuvant therapy, with a pathological complete response in 6 (23%) and pathological partial response in 1 (4%) for an overall response rate of 35% (95% confidence limits 17 to 56%). The overall median survival time is currently undefined. Of the patients 15 (58%) are alive with a median followup of 48.6 months. Response rates from this neoadjuvant chemotherapy appear to be similar to those reported with methotrexate, vinblastine, doxorubicin and cisplatin, and may represent a therapeutically equivalent regimen but neither may be curative in the majority of the patients.Keywords
This publication has 11 references indexed in Scilit:
- Systemic Preoperative Chemotherapy with Cisplatin, Methotrexate and Vinblastine for Locally Advanced Bladder Cancer: Local Tumor Response and Early Followup ResultsJournal of Urology, 1991
- Perioperative Methotrexate, Vinblastine, Doxorubicin and Cisplatin (M-VAC) for Poor Risk Transitional Cell Carcinoma of the Bladder: An Eastern Cooperative Oncology Group Pilot StudyJournal of Urology, 1990
- Usefulness and Limitations of Methotrexate, Vinblastine, Doxorubicin And Cisplatin for the Treatment of Advanced Urothelial CancerJournal of Urology, 1990
- A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors.Journal of Clinical Oncology, 1990
- M-Vac (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) Chemotherapy for Transitional Cell Carcinoma: The Princess Margaret Hospital ExperienceJournal of Urology, 1989
- Neoadjuvant M-Vac (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) Effect on the Primary Bladder LesionJournal of Urology, 1988
- Neoadjuvant Chemotherapy for Locally Advanced Transitional Cell Carcinoma of the Bladder: Do Local Findings Suggest a Potential for Salvage of the Bladder?Mayo Clinic Proceedings, 1988
- Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study.Journal of Clinical Oncology, 1985
- Preliminary Results of M-VAC (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Transitional Cell Carcinoma of the UrotheliumJournal of Urology, 1985
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958